Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Dihexa vs Noopept
An educational, source-based comparison of Dihexa and Noopept — how each peptide works, what it's researched for, and what to know before going deeper.
A hexapeptide derived from angiotensin IV that crosses the blood-brain barrier and potentiates hepatocyte growth factor (HGF) / c-Met signaling, associated with new synapse formation in preclinical models.
- Synaptogenesis and dendritic spine density
- Alzheimer's and cognitive aging models
- Memory consolidation in rodents
- • No human clinical trial data; theoretical proliferation concerns via HGF/c-Met.
- • Not FDA-approved.
Dipeptide-derived nootropic researched for memory and neuroprotection.
A synthetic dipeptide (N-phenylacetyl-L-prolylglycine ethyl ester) derived from the endogenous nootropic cycloprolylglycine. Research suggests it potentiates AMPA receptor activity, increases BDNF and NGF expression, and provides antioxidant protection in neuronal tissue.
- Memory consolidation and retrieval
- Neuroprotection in ischemic injury
- Anxiety and emotional modulation
- Age-related cognitive decline
- • Approved in Russia; not FDA-approved in the US.
- • Generally well tolerated with few reported side effects.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
Two cited studies; independent replication needed.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Dihexa | Dihexa, a potent procognitive HGF mimetic | Journal of Pharmacology and Experimental Therapeutics | 2012 | Robust improvements in spatial learning in aged rodent models. |
| Noopept | Noopept neuroprotective effects in cerebral ischemia | Bulletin of Experimental Biology and Medicine | 2009 | Demonstrated protective effects against glutamate neurotoxicity in vitro. |
| Noopept | Noopept in mild cognitive impairment | Advances in Gerontology | 2012 | Improved cognitive scores in elderly patients with mild cognitive disorders. |
Side-effect & safety grid
- No human clinical trial data; theoretical proliferation concerns via HGF/c-Met.
- Not FDA-approved.
- Approved in Russia; not FDA-approved in the US.
- Generally well tolerated with few reported side effects.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Dihexa vs Noopept — Key differences
- Class: Dihexa is classified as Nootropic · Synaptogenesis, while Noopept is Nootropic · Neuroprotection.
- Primary research focus: Dihexa — synaptogenesis and dendritic spine density; Noopept — memory consolidation and retrieval.
- Tag: Cognition vs Cognition.